regulatory landscape and comparisons

a tale of two regulatory worlds

Semax occupies an unusual position in the neuropeptide landscape: formally approved in Russia and Ukraine but essentially unknown to Western regulatory agencies. this unit examines why that gap exists, how Semax compares to Selank, Cerebrolysin, and community modifications like N-Acetyl Semax Amidate (NASA), and what the regulatory asymmetry means for quality and access.